Edgar Filing: Codner Iris Beck

Ownership Submission

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Â Codner Iris Beck

2. Date of Event Requiring Statement (Month/Day/Year)
02/06/2018

3. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [TEVA]

(Last)

(First)

(Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.,Â 5 BASEL STREET

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director	_____ 10% Owner
__X__ Officer (give title below)	_____ Other (specify below)
EVP Global Brand&Communication

5. If Amendment, Date Original Filed(Month/Day/Year)

(Street)

PETACH TIKVA,Â L3Â 4951033

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares ⁽¹⁾	12,455.0357	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Options (right to buy)	Â ⁽²⁾	05/12/2023	Ordinary Shares ⁽¹⁾	16,668	$ 39.24	D	Â
Stock Options (right to buy)	Â ⁽³⁾	03/11/2024	Ordinary Shares ⁽¹⁾	25,003	$ 48.76	D	Â
Stock Options (right to buy)	Â ⁽⁴⁾	02/11/2025	Ordinary Shares ⁽¹⁾	54,623	$ 57.35	D	Â
Stock Options (right to buy)	Â ⁽⁵⁾	02/11/2026	Ordinary Shares ⁽¹⁾	44,960	$ 55.75	D	Â
Stock Options (right to buy)	Â ⁽⁶⁾	02/14/2027	Ordinary Shares ⁽¹⁾	51,023	$ 34.9	D	Â
Restricted Share Units	Â ⁽⁷⁾	Â ⁽⁷⁾	Ordinary Shares ⁽¹⁾	9,637	$ ⁽⁸⁾	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Codner Iris Beck C/O TEVA PHARMACEUTICAL INDUSTRIES LTD. 5 BASEL STREET PETACH TIKVA,Â L3Â 4951033	Â	Â	Â EVP Global Brand&Communication	Â

Signatures

/s/ Dov Bergwerk, as attorney-in-fact for Iris Beck-Codner		02/12/2018
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
(2)	Stock options were granted on May 13, 2013 and vested on May 13, 2016.
(3)	Stock options were granted on March 12, 2014, with 8,334 having vested on each of March 12, 2015 and March 12, 2016 and 8,335 having vested on March 12, 2017.
(4)	Stock options were granted on February 12, 2015, with 18,207 having vested on each of February 12, 2017 and February 12, 2018, and 18,209 vesting on February 12, 2019.
(5)	Stock options were granted on February 12, 2016, with 14,986 having vested on February 12, 2018, 14,986 vesting on February 12, 2019 and 14,988 vesting on February 12, 2020.
(6)	Stock options were granted on February 14, 2017, with 17,007 vesting on each of February 14, 2019 and February 14, 2020 and 17,009 vesting on February 14, 2021.
(7)	Restricted share units were granted on February 14, 2017, with 3,212 vesting on each of February 14, 2019 and February 14, 2020 and 3,213 vesting on February 14, 2021.
(8)	Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
Â Remarks: ExhibitÂ List Â Â Â Â Â ExhibitÂ 24Â -Â PowerÂ ofÂ Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.